Every 10-Q that Sensei Biotherapeutics, Inc. (SNSE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SNSE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNSE filings page.
Sensei Biotherapeutics transformed its business in the quarter by acquiring Faeth Therapeutics and making PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, its lead cancer program. The deal was paired with a $200 million private placement of Series B redeemable convertible preferred stock.
The company reported a net loss of $170.2 million, driven largely by a $133.0 million acquired in-process R&D charge and one-time stock-based compensation and tax gross-up costs tied to the acquisition. Cash, cash equivalents and marketable securities rose to $202.8 million, but management disclosed substantial doubt about its ability to continue as a going concern because holders of the new preferred stock could demand cash settlement if stockholder approval and timely share delivery are not achieved.
Sensei Biotherapeutics (SNSE) reported Q3 results and outlined major changes to its business. The company posted a net loss of $4.569M, improved from $7.253M a year ago, as operating expenses fell to $4.851M. Cash, cash equivalents and marketable securities totaled $25.0M as of September 30, 2025.
Sensei discontinued development of its lead program, solnerstotug, and began a review of strategic alternatives, which could include asset sales, licensing, a merger, or an orderly wind-down. To preserve cash, it plans a workforce reduction of approximately 65%, expecting cash charges of about $1.6M primarily for severance. Management concluded there is substantial doubt about the company’s ability to continue as a going concern.
The company effected a 1‑for‑20 reverse stock split on June 16, 2025. Shares outstanding were 1,261,290 as of November 10, 2025. With R&D at $2.536M and G&A at $2.315M in Q3, Sensei expects lower expenses as operations wind down during the strategic review.